The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Therapeutic Targeting of Oncogenic K‐Ras by a Covalent Catalytic Site Inhibitor
Open accessAbstract
We report the synthesis of a GDP analogue, SML‐8‐73‐1, and a prodrug derivative, SML‐10‐70‐1, which are selective, direct‐acting covalent inhibitors of the K‐Ras G12C mutant relative to wild‐type Ras. Biochemical and biophysical measurements suggest that modification of K‐Ras with SML‐8‐73‐1 renders the protein in an inactive state. These first‐in‐class covalent K‐Ras inhibitors demonstrate that irreversible targeting of the K‐Ras guanine‐nucleotide binding site is potentially a viable therapeutic strategy for inhibition of Ras signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“SM-10-70-1 showed increased cellular permeability and competitively inhibited KRASG12C through covalent binding.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [91]
In the citing paper
“In addition, KRAS-dependent signaling pathways, such as the Akt and Erk pathways, are also inhibited.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [91]
In the citing paper
“Therefore, SM-10-70-1 (22) was synthesized by modifying phosphoric acid groups of SML-8-73-1 with “caging” technology.91”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [91]
In the citing paper
“Moreover, the ability of SM-10-70-1 to exhibit anti-proliferative activity was demonstrated in several cancer cell lines expressing the KRASG12C mutation.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [91]
In the citing paper
“was recently found to be targetable by small-molecule inhibitors (8, 9).”
In the citing paper
“SML-10-70-1, a GDP-derived analog that covalently modifies cysteine 12 of K-RasG12C, was identified with anti-proliferative activity in KRASG12C mutant models.53”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [53]
In the citing paper
“However, SML-10-70-1 functioned as a nonspecific K-RasG12C inhibitor, as K-RasG12S-bearing cells also responded to this compound.53”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [53]
In the citing paper
“Accordingly, inhibitors of this type are KRASG12C specific; therefore, they do not affect RAS signalling in non-malignant cells65,70–72 and, at least theoretically, have a low risk of on-target, off-tumour toxicities.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [72]
In the citing paper
“Lim et al. reported the synthesis of a GDP analog, SML-8-73-1, which contains an electrophilic chloroacetamide attached to the β-phosphate. This analog can covalently modify cysteine 12 of KRasG12C and, as a result, it competes with GTP and GDP for active site binding in a cellular context (38).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [38]
In the citing paper
“Earlier studies have identified small molecules selectively recognizing and irreversibly inactivating one specific KRAS-mutant allele harboring a G12C amino acid substitution (37, 38).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Barbacid, M. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004023 · Cited by 3,885
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc969 · Cited by 3,354
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2559 · Cited by 2,648
Self-citationCOSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063
Mammalian Ras interacts directly with the serine/threonine kinase raf
Vojtek, A. B., Hollenberg, S. M., & Cooper, J. A. (1993) · Cell · doi:10.1016/0092-8674(93)90307-c · Cited by 1,934
The Guanine Nucleotide-Binding Switch in Three Dimensions
Vetter, I. R., & Wittinghofer, A. (2001) · Science · doi:10.1126/science.1062023 · Cited by 1,875
The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants
Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543
Milburn, M. V., Tong, L., deVos, A. M., Brünger, A. T., Yamaizumi, Z., Nishimura, S., & Kim, S. (1990) · Science · doi:10.1126/science.2406906 · Cited by 1,062
Research works printed but not linked: 1
- Bos J. L., 1989, Cancer Res., 49, 4682
Cited by
Sorted by citations
Items 101–200 of 307
Allosteric inhibition of antiapoptotic MCL-1
Lee, S., Wales, T. E., Escudero, S., Cohen, D. T., Luccarelli, J., Gallagher, C. G., Cohen, N. A., Huhn, A. J., Bird, G. H., Engen, J. R., et al. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3223 · Cited by 59
Self-citationZhao, Q., Peng, C. Y., Huang, H., Liu, S., Zhong, Y., Huang, W., He, G., & Han, B. (2018) · Chemical Communications · doi:10.1039/c8cc04732d · Cited by 60
Targeting Ras-, Rho-, and Rab-family GTPases via a conserved cryptic pocket
Morstein, J., Bowcut, V., Fernando, M. C., Yang, Y., Zhu, L., Jenkins, M. L., Evans, J. T., Guiley, K. Z., Peacock, D. M., Krahnke, S., et al. (2024) · Cell · doi:10.1016/j.cell.2024.08.017 · Cited by 62
Recent advances in cancer drug discovery targeting RAS
Wilson, C., & Tolias, P. P. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.08.002 · Cited by 59
Shin, S. H., Kim, H. J., Hwang, D. W., Lee, J. H., Song, K. B., Jun, E., Shim, I. K., Hong, S.-M., Kim, H. J., Park, K.-M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14901 · Cited by 57
Total Chemical Synthesis and Folding of All- l and All- d Variants of Oncogenic KRas(G12V)
Levinson, A. M., McGee, J. H., Roberts, A. G., Creech, G. S., Wang, T., Peterson, M. T., Hendrickson, R. C., Verdine, G. L., & Danishefsky, S. J. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b02988 · Cited by 57
Targeting the undruggable oncogenic KRAS: the dawn of hope
Asimgil, H., Ertetik, U., Çevik, N. C., Ekizce, M., Doğruöz, A., Gökalp, M., Sever, E. A., Istvánffy, R., Friess, H., Ceyhan, G. O., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.153688 · Cited by 57
Weisberg, E., Nonami, A., Chen, Z., Liu, F., Zhang, J., Sattler, M., Nelson, E. A., Cowens, K. B., Christie, A. L., Mitsiades, C. S., et al. (2014) · Leukemia · doi:10.1038/leu.2014.149 · Cited by 53
Self-citationVivekanandhan, S., & Mukhopadhyay, D. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.01.014 · Cited by 53
Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges
Choucair, K., Imtiaz, H., Uddin, M. H., Nagasaka, M., Al-Hallak, M. N., Philip, P. A., El-Rayes, B., Pasche, B., & Azmi, A. S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02473-8 · Cited by 67
KRAS Switch Mutants D33E and A59G Crystallize in the State 1 Conformation
Lu, J., Bera, A. K., Gondi, S. R., & Westover, K. D. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00974 · Cited by 51
Self-citationTargeting the RAS-dependent chemoresistance: The Warburg connection
Serna‐Blasco, R., Sanz-Álvarez, M., Aguilera, Ó., & García‐Foncillas, J. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.01.016 · Cited by 55
Cysteine-based regulation of redox-sensitive Ras small GTPases
Messina, S., Simone, G. D., & Ascenzi, P. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101282 · Cited by 52
Kopra, K., Vuorinen, E., Blanco, M. A., Wang, Q., Eskonen, V., Gillette, W., Pulliainen, A. T., Holderfield, M. T., & Härmä, H. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.9b05126 · Cited by 52
Sphingomyelin Metabolism Is a Regulator of K-Ras Function
van der Hoeven, D., Cho, K., Zhou, Y., Ma, X., Chen, W., Naji, A. K., Montufar‐Solis, D., Zuo, Y., Kovar, S. E., Levental, K. R., et al. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00373-17 · Cited by 51
KRAS: Reasons for optimism in lung cancer
Lindsay, C. R., Jamal‐Hanjani, M., Forster, M. D., & Blackhall, F. H. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.05.001 · Cited by 52
Marín‐Ramos, N. I., Balabasquer, M., Ortega-Nogales, F. J., Torrecillas, I. R., Gil-Ordóñez, A., Marcos‐Ramiro, B., Aguilar-Garrido, P., Cushman, I., Romero, A., Medrano, F. J., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00145 · Cited by 51
Intrinsically disordered proteins: Ensembles at the limits of Anfinsen's dogma
Kulkarni, P., Leite, V. B. P., Roy, S., Bhattacharyya, S., Mohanty, A. R., Achuthan, S., Singh, D., Appadurai, R., Govindan Rangarajan, C., Weninger, K., et al. (2022) · Biophysics Reviews · doi:10.1063/5.0080512 · Cited by 49
Chloroacetamide-Linked Nucleotides and DNA for Cross-Linking with Peptides and Proteins
Olszewska, A., Pohl, R., Brázdová, M., Fojta, M., & Hocek, M. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00342 · Cited by 47
Blocking Ras inhibition as an antitumor strategy
Marín‐Ramos, N. I., Ortega‐Gutiérrez, S., & López-Rodríguez, M. L. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.01.017 · Cited by 46
Cammarata, M. B., Schardon, C. L., Mehaffey, M. R., Rosenberg, J. A., Singleton, J. P., Fast, W. L., & Brodbelt, J. S. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b04474 · Cited by 45
Vatansever, S., Gumus, Z. H., & Erman, B. (2016) · Scientific Reports · doi:10.1038/srep37012 · Cited by 45
How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization
Brock, E. J., Ji, K., Reiners, J. J., & Mattingly, R. R. (2015) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557515666151001154002 · Cited by 41
Wang, Q., Mehmood, A., Wang, H., Xu, Q., Xiong, Y., & Wei, D. (2019) · Molecules · doi:10.3390/molecules24101951 · Cited by 41
Drugging the Next Undruggable KRAS Allele-Gly12Asp
Zheng, Q., Peacock, D. M., & Shokat, K. M. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00099 · Cited by 41
Direct Ras inhibitors identified from a structurally rigidified bicyclic peptide library
Upadhyaya, P., Qian, Z., Habir, N. A. A., & Pei, D. (2014) · Tetrahedron · doi:10.1016/j.tet.2014.05.113 · Cited by 40
Targeting Pathways Downstream of KRAS in Lung Adenocarcinoma
Zhu, Z., Golay, H. G., & Barbie, D. A. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.108 · Cited by 40
Challenges in Ras therapeutics in pancreatic cancer
Choi, M., Bien, H., Mofunanya, A., & Powers, S. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.015 · Cited by 39
Lu, J., Harrison, R. A., Li, L., Zeng, M., Gondi, S. R., Scott, D. A., Gray, N. S., Engen, J. R., & Westover, K. D. (2017) · Structure · doi:10.1016/j.str.2017.07.003 · Cited by 38
Self-citationBehind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers
Arner, E. N., Du, W., & Brekken, R. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01049 · Cited by 40
Structural Dynamics in Ras and Related Proteins upon Nucleotide Switching
Harrison, R. A., Lu, J., Carrasco, M. A., Hunter, J., Manandhar, A., Gondi, S. R., Westover, K. D., & Engen, J. R. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.10.017 · Cited by 37
Self-citationFicarro, S. B., Browne, C. M., Card, J. D., Alexander, W. M., Zhang, T., Park, E., McNally, R., Dhe‐Paganon, S., Seo, H., Lamberto, I., et al. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b03394 · Cited by 36
Self-citationApproaches to inhibiting oncogenic K-Ras
Gorfe, A. A., & Cho, K. (2019) · Small GTPases · doi:10.1080/21541248.2019.1655883 · Cited by 36
RAS degraders: The new frontier for RAS-driven cancers
Escher, T. E., & Satchell, K. J. F. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.03.017 · Cited by 36
Baldelli, E., Bellezza, G., Haura, E. B., Crinò, L., Cress, W. D., Deng, J., Ludovini, V., Sidoni, A., Schabath, M. B., Puma, F., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5941 · Cited by 34
Structure, signaling and the drug discovery of the Ras oncogene protein
Han, C. W., Jeong, M. S., & Jang, S. B. (2017) · BMB Reports · doi:10.5483/bmbrep.2017.50.7.062 · Cited by 38
Regulation of large and small G proteins by ubiquitination
Dohlman, H. G., & Campbell, S. L. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.rev119.011068 · Cited by 40
Covalent Targeting of Ras G12C by Rationally Designed Peptidomimetics
Yoo, D. Y., Hauser, A. D., Joy, S. T., Bar‐Sagi, D., & Arora, P. S. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00204 · Cited by 35
Müller, M. P., Jeganathan�, S., Heidrich, A., Campos, J., & Goody, R. S. (2017) · Scientific Reports · doi:10.1038/s41598-017-03973-6 · Cited by 36
Mills, R. D., Mulhern, T. D., Liu, F., Culvenor, J. G., & Cheng, H. (2014) · Human Mutation · doi:10.1002/humu.22515 · Cited by 34
Development of Pyridazinone Chemotypes Targeting the PDEδ Prenyl Binding Site
Murarka, S., Martín‐Gago, P., Schultz‐Fademrecht, C., Saabi, A. A., Baumann, M., Fansa, E. K., Ismail, S., Nußbaumer, P., Wittinghofer, A., & Waldmann, H. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201603222 · Cited by 34
Synthetic lethal approaches for assessing combinatorial efficacy of chemotherapeutic drugs
Jackson, R. A., & Chen, E. S. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.01.014 · Cited by 33
Tuning Cyclometalated Gold(III) for Cysteine Arylation and Ligand-Directed Bioconjugation
Gukathasan, S., Parkin, S., Black, E. P., & Awuah, S. G. (2021) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.1c01517 · Cited by 33
Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers
Pandey, D., Chauhan, S. C., Kashyap, V. K., & Roy, K. K. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116771 · Cited by 32
Karimi, N., & Moghaddam, S. J. (2023) · Cells · doi:10.3390/cells12050749 · Cited by 37
Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells
Du, R., Sullivan, D. K., Azizian, N. G., Liu, Y., & Li, Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-07967-6 · Cited by 31
A Pan-GTPase Inhibitor as a Molecular Probe
Hong, L., Guo, Y., BasuRay, S., Agola, J. O., Romero, E., Simpson, D. S., Schroeder, C. E., Simons, P. C., Waller, A., Garcia, M. J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134317 · Cited by 31
Mehaffey, M. R., Schardon, C. L., Novelli, E. T., Cammarata, M. B., Webb, L. J., Fast, W. L., & Brodbelt, J. S. (2019) · Chemical Science · doi:10.1039/c9sc01032g · Cited by 31
RAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics
Kattan, W. E., & Hancock, J. F. (2020) · Biochemical Journal · doi:10.1042/bcj20190839 · Cited by 33
Making NSCLC Crystal Clear: How Kinase Structures Revolutionized Lung Cancer Treatment
Vilachã, J. F., Mitchel, S. C., Akele, M. Z., Evans, S., & Groves, M. R. (2020) · Crystals · doi:10.3390/cryst10090725 · Cited by 29
Chen, F., Li, X., Zhu, H.-P., & Huang, W. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00280 · Cited by 30
Targeting eukaryotic proteases for natural products-based drug development
Al‐Awadhi, F. H., & Luesch, H. (2020) · Natural Product Reports · doi:10.1039/c9np00060g · Cited by 30
Structural basis of the atypical activation mechanism of KRASV14I
Bera, A. K., Lu, J., Wales, T. E., Gondi, S. R., Gurbani, D., Nelson, A., Engen, J. R., & Westover, K. D. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.009131 · Cited by 31
Self-citationSelective Inhibition of Mutant Ras Protein through Covalent Binding
Rudolph, J., & Stokoe, D. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201400233 · Cited by 29
Inhibition of prenylated KRAS in a lipid environment
Jansen, J. M., Wartchow, C. A., Jahnke, W., Fong, S. K., Tsang, T., Pfister, K. B., Zavorotinskaya, T., Bussiere, D. E., Cheng, J. M., Crawford, K. R., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174706 · Cited by 29
Inhibition of Nonfunctional Ras
Nussinov, R., Jang, H., Gürsoy, A., Keskin, Ö., & Gaponenko, V. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2020.12.012 · Cited by 29
Small-Molecule RAS Inhibitors as Anticancer Agents: Discovery, Development, and Mechanistic Studies
Shetu, S. A., & Bandyopadhyay, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073706 · Cited by 31
Dubiella, C., Baur, R., Cui, H., Huber, E. M., & Groll, M. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201506631 · Cited by 28
From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers
Saliani, M., Jalal, R., & Ahmadian, M. R. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2018.0530 · Cited by 27
Computational allosteric ligand binding site identification on Ras proteins
McCarthy, M. J., Prakash, P., & Gorfe, A. A. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv100 · Cited by 29
Molecular dynamics simulations for the structure-based drug design: targeting small-GTPases proteins
Parise, A., Cresca, S., & Magistrato, A. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2387856 · Cited by 27
Structure-based inhibitor design of mutant RAS proteins—a paradigm shift
Nyíri, K., Koppány, G., & Vértessy, B. G. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09914-6 · Cited by 27
Understand KRAS and the Quest for Anti-Cancer Drugs
Han, C. W., Jeong, M. S., & Jang, S. B. (2021) · Cells · doi:10.3390/cells10040842 · Cited by 27
Current status of the development of Ras inhibitors
Shima, F., Matsumoto, S., Yoshikawa, Y., Kawamura, T., Isa, M., & Kataoka, T. (2015) · The Journal of Biochemistry · doi:10.1093/jb/mvv060 · Cited by 28
Hafezi, S., Saber-Ayad, M. M., & Abdel‐Rahman, W. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910219 · Cited by 28
Multiple Strategies to Develop Small Molecular KRAS Directly Bound Inhibitors
Zhou, X., Ji, Y., & Zhou, J. (2023) · Molecules · doi:10.3390/molecules28083615 · Cited by 27
Sobkowski, M., Kraszewski, A., & Stawiński, J. (2014) · Topics in current chemistry · doi:10.1007/128_2014_562 · Cited by 26
Chemical Biology Tools for Regulating RAS Signaling Complexity in Space and Time
van Hattum, H., & Waldmann, H. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.001 · Cited by 27
Liu, Z., Wang, M., Wang, H., Fang, L., & Gou, S. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112269 · Cited by 25
Small molecule inhibitors of RAS proteins with oncogenic mutations
Orgován, Z., & Keserű, G. M. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09911-9 · Cited by 25
RAS‐targeted cancer therapy: Advances in drugging specific mutations
Liu, C., Ye, D., Yang, H., Chen, X., Su, Z., Li, X., Ding, M., & Liu, Y. (2023) · MedComm · doi:10.1002/mco2.285 · Cited by 25
Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers
Mattox, T. E., Chen, X., Maxuitenko, Y. Y., Keeton, A. B., & Piazza, G. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010141 · Cited by 25
Chen, F.-Y., Li, X., Zhan, G., Liu, H., Kang, B., Zhang, S.-C., Peng, C. Y., & Han, B. (2020) · Tetrahedron Letters · doi:10.1016/j.tetlet.2020.151806 · Cited by 24
Nakayama, A., Nagashima, T., Nishizono, Y., Kuramoto, K., Mori, K., Homboh, K., Yuri, M., & Shimazaki, M. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01629-x · Cited by 24
Inhibition of Ras Signaling by Blocking Ras–Effector Interactions with Cyclic Peptides
Upadhyaya, P., Qian, Z., Selner, N. G., Clippinger, S. R., Wu, Z., Briesewitz, R., & Pei, D. (2015) · Angewandte Chemie · doi:10.1002/ange.201502763 · Cited by 24
Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor
Wijeratne, A. B., Xiao, J., Reutter, C. T., Furness, K., Leon, R., Zia‐Ebrahimi, M., Cavitt, R. N., Strelow, J. M., Horn, R. D. V., Peng, S.-B., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00110 · Cited by 24
Covalent inhibitors of the GTPase KRASG12C: a review of the patent literature
Kettle, J. G., & Cassar, D. J. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1709443 · Cited by 23
Direct GDP-KRAS G12C inhibitors and mechanisms of resistance: the tip of the iceberg
Rosen, J. C., Sacher, A. G., & Tsao, M. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231160141 · Cited by 22
Replication in Bioanalytical Studies with Hdx MS: Aim as High as Possible
Moroco, J. A., & Engen, J. R. (2015) · Bioanalysis · doi:10.4155/bio.15.46 · Cited by 22
Self-citationSciver, R. E. V., Lee, M., Lee, C. G. L., Lafever, A., Svyatova, E. A., Kanda, K., Collier, A. L., van Reesema, L. L. S., Tang-Tan, A. M., Zheleva, V. P., et al. (2018) · Cancers · doi:10.3390/cancers10050142 · Cited by 21
Emerging RAS-directed therapies for cancer
Conroy, M. R., Cowzer, D., Kölch, W., & Duffy, A. G. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.07 · Cited by 23
Progress on Covalent Inhibition of KRASG12C
Westover, K. D., Janne, P. A., & Gray, N. S. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0092 · Cited by 21
Self-citationPast, Present, and Future of Targeting Ras for Cancer Therapies
Tan, Z., & Zhang, S. (2015) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557515666151001154111 · Cited by 21
The small GTPases Ras and Rheb studied by multidimensional NMR spectroscopy: structure and function
Schöpel, M., Potheraveedu, V. N., Al-Harthy, T. S., Abdel-Jalil, R. J., Heumann, R., & Stoll, R. (2017) · Biological Chemistry · doi:10.1515/hsz-2016-0276 · Cited by 21
Recent advances in the biology and therapy of medullary thyroid carcinoma
Nelkin, B. D. (2017) · F1000Research · doi:10.12688/f1000research.12645.1 · Cited by 21
Elucidating the Mode of Action of a Typical Ras State 1(T) Inhibitor
Rosnizeck, I. C., Filchtinski, D., Lopes, R. P., Kieninger, B., Herrmann, C., Kalbitzer, H. R., & Spoerner, M. (2014) · Biochemistry · doi:10.1021/bi401689w · Cited by 21
Searching for the Chokehold of NRAS Mutant Melanoma
Posch, C., Vujic, I., Monshi, B., Sanlorenzo, M., Weihsengruber, F., Rappersberger, K., & Ortiz-Urda, S. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.03.006 · Cited by 19
Mao, Y., Yao, H., Wang, H., Cheng, P., & Long, D. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201608653 · Cited by 20
Weisberg, E., Nonami, A., Chen, Z., Nelson, E. A., Chen, Y., Liu, F., Cho, H., Zhang, J., Sattler, M., Mitsiades, C. S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0902 · Cited by 20
Self-citationQuantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors
Stites, E. C., & Shaw, A. S. (2018) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12291 · Cited by 20
Milroy, L. ‐., & Ottmann, C. (2014) · ACS Chemical Biology · doi:10.1021/cb500555h · Cited by 18
Therapeutic Approaches to RAS Mutation
Scott, A. J., Lieu, C. H., & Messersmith, W. A. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000187 · Cited by 19
Addressing the Right Targets in Oncology: Challenges and Alternative Approaches
Stock, J. K., Jones, N. P., Hammonds, T. R., Roffey, J., & Dillon, C. (2015) · SLAS DISCOVERY · doi:10.1177/1087057114564349 · Cited by 19
Development of a Nucleotide Exchange Inhibitor That Impairs Ras Oncogenic Signaling
Marín‐Ramos, N. I., Piñar, C., Vázquez‐Villa, H., Martín‐Fontecha, M., González, Á., Canales, Á., Algar, S., Mayo, P. P., Jiménez‐Barbero, J., Gajate, C., et al. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201604905 · Cited by 19
Targeting KRAS in NSCLC: Old Failures and New Options for “Non-G12c” Patients
Jacobs, F., Cani, M., Malapelle, U., Novello, S., Napoli, V. M., & Bironzo, P. (2021) · Cancers · doi:10.3390/cancers13246332 · Cited by 18
High-Throughput Dual Screening Method for Ras Activities and Inhibitors
Kopra, K., van Adrichem, A. J., Salo‐Ahen, O. M. H., Peltonen, J. T. K., Wennerberg, K., & Härmä, H. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.6b04904 · Cited by 17
Correlation of O2 transport on the micro and macro scale.
Honig, C. R., & Gayeski, T. E. (1982) · PubMed · Cited by 17
Zhang, Y., Larraufie, M.-H., Musavi, L., Akkiraju, H., Brown, L. M., & Stockwell, B. R. (2018) · Biochemistry · doi:10.1021/acs.biochem.7b01113 · Cited by 16
Pharmacological strategies to target oncogenic KRAS signaling in pancreatic cancer
Chuang, H.-C., Huang, P.-H., Kulp, S. K., & Chen, C. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.01.006 · Cited by 16
Targeting Mutant KRAS for Anticancer Therapy
Chen, F., Alphonse, M. P., Liu, Y., & Liu, Q. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190902151307 · Cited by 15
Metadata
- Authors
- Lim, S. M., Westover, K. D., Ficarro, S. B., Harrison, R. A., Choi, H. G., Pacold, M. E., Carrasco, M., Hunter, J., Kim, N. D., Xie, T., Sim, T., Jänne, P. A., Meyerson, M., Marto, J. A., Engen, J. R., & Gray, N. S.
- Affiliations
- Harvard University (US)
- The University of Texas Southwestern Medical Center (US)
- Dana-Farber Cancer Institute (US)
- Northeastern University (US)
- Daegu-Gyeongbuk Medical Innovation Foundation (KR)
- Korea Institute of Science and Technology (KR)
- Broad Institute (US)
- Corresponding author
- Gray, Nathanael S.
- ORCID
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2013-11-20
- Volume
- 53
- Issue
- 1
- Pages
- 199-204
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- PMC
- PMC3914205
- OpenAlex
- W2141965353
- Cited by
- 300
- References
- 30
- Citations by year
- 2026: 4 · 2025: 13 · 2024: 15 · 2023: 10 · 2022: 18 · 2021: 21 · 2020: 31 · 2019: 34 · 2018: 27 · 2017: 36 · 2016: 37 · 2015: 29 · 2014: 24
- FWCI
- 13.60
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Angewandte Chemie International Edition (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA130876)
- National Institute of General Medical Sciences (R01GM101135, GM101135)
- National Institute of Neurological Disorders and Stroke (P01NS047572)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- covalent inhibitors, prodrugs, Ras signaling inhibition, oncogenic Ras, small molecule inhibitors
- MeSH terms
- Drug Design, Signal Transduction, ras Proteins, Catalytic Domain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
